SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Navarro-Sarabia F, Ariza-Ariza R, Hernandez-Cruz B, Villanueva I. Adalimumab for treating rheumatoid arthritis. Cochrane Database Syst Rev 2005; 3: CD005113.
  • 2
    Genovese MC, Bathon JM, Fleischmann RM, Moreland LW, Martin RW, Whitmore JB, et al. Longterm safety, efficacy, and radiographic outcome with etanercept treatment in patients with early rheumatoid arthritis. J Rheumatol 2005; 32: 123242.
  • 3
    Liang GC, Cordero M, Dyer A, Chang RW. Current tumor necrosis factor-alpha inhibitor use is associated with a higher probability of remissions in patients with rheumatoid arthritis. J Rheumatol 2005; 32: 16625.
  • 4
    St. Clair EW, van der Heijde DM, Smolen JS, Maini RN, Bathon JM, Emery P, et al, and the Active-Controlled Study of Patients Receiving Infliximab for the Treatment of Rheumatoid Arthritis of Early Onset Study Group. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. Arthritis Rheum 2004; 50: 343243.
  • 5
    Balsa A, Carmona L, Gonzalez-Alvaro I, Belmonte MA, Tena X, Sanmarti R, and the EMECAR Study Group. Value of Disease Activity Score 28 (DAS28) and DAS28–3 compared to American College of Rheumatology-defined remission in rheumatoid arthritis. J Rheumatol 2004; 31: 406.
  • 6
    Breedveld FC, Kalden JR. Appropriate and effective management of rheumatoid arthritis. Ann Rheum Dis 2004; 63: 62733.
  • 7
    Classification and Response Criteria Subcommittee of the American College of Rheumatology Committee on Quality Measures. Development of classification and response criteria for rheumatic diseases. Arthritis Rheum 2006; 55: 34852.
  • 8
    Pincus T, Sokka T, Kavanaugh A. Relative versus absolute goals of therapies for RA: ACR 20 or ACR 50 responses versus target values for “near remission” of DAS or single measures. Clin Exp Rheumatol 2004; 22(5 Suppl 35 ): S506.
  • 9
    Dougados M. It's good to feel better but it's better to feel good [editorial]. J Rheumatol 2005; 32: 12.
  • 10
    Pinals RS, Masi AT, Larsen RA, and the Subcommittee for Criteria of Remission in Rheumatoid Arthritis of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Preliminary criteria for clinical remission in rheumatoid arthritis. Arthritis Rheum 1981; 24: 130815.
  • 11
    Prevoo ML, van Gestel AM, van 't Hof MA, van Rijswijk MH, van de Putte LB, van Riel PL. Remission in a prospective study of patients with rheumatoid arthritis: American Rheumatism Association preliminary remission criteria in relation to the disease activity score. Br J Rheumatol 1996; 35: 11015.
  • 12
    Pincus T, Kavanaugh A, Aletaha D, Smolen J. Complexities in defining remission in rheumatic diseases. Clin Exp Rheumatol 2006; 24(6 Suppl 43 ): S16.
  • 13
    Aletaha D, Smolen JS. Remission of rheumatoid arthritis: should we care about definitions? Clin Exp Rheumatol 2006; 24 Suppl 43: S4551.
  • 14
    Fransen J, van Riel PL. DAS remission cut points. Clin Exp Rheumatol 2006; 24(6 Suppl 43 ): S2932.
  • 15
    Makinen H, Hannonnen P, Sokka T. Definitions of remission for rheumatoid arthritis and review of selected clinical cohorts and randomised clinical trials for the rate of remission. Clin Exp Rheumatol 2006; 24(6 Suppl 43 ): S228.
  • 16
    Ranganath VK, Khanna D, Paulus HE. ACR remission criteria and response criteria. Clin Exp Rheumatol 2006; 24(6 Suppl 43 ): S1421.
  • 17
    Aletaha D, Ward MM, Machold KP, Nell VP, Stamm T, Smolen JS. Remission and active disease in rheumatoid arthritis: defining criteria for disease activity states. Arthritis Rheum 2005; 52: 262536.
  • 18
    Makinen H, Kautiainen H, Hannonnen P, Sokka T. Is DAS28 an appropriate tool to assess remission in rheumatoid arthritis? Ann Rheum Dis 2005; 64: 14103.
  • 19
    Sesin CA, Bingham CO. Remission in rheumatoid arthritis: wishful thinking or clinical reality? Semin Arthritis Rheum 2005; 35: 18596.
  • 20
    Prevoo ML, van 't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LB, van Riel PL. Modified disease activity scores that include twenty-eight–joint counts: development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995; 38: 448.
  • 21
    Fransen J, Creemers MC, van Riel PL. Remission in rheumatoid arthritis: agreement of the disease activity score (DAS28) with the ARA preliminary remission criteria. Rheumatology (Oxford) 2004; 43: 12525.
  • 22
    Aletaha D, Smolen J. The Simplified Disease Activity Index (SDAI) and the Clinical Disease Activity Index (CDAI): a review of their usefulness and validity in rheumatoid arthritis. Clin Exp Rheumatol 2005; 23(5 Suppl 39 ): S1008.
  • 23
    Geborek P, Gulfe A, Aletaha D, Kristensen LE, Saxne T. New and established criteria for remission and disease activity in an observational RA cohort treated with etanercept [abstract]. Arthritis Rheum 2006; 54 Suppl 9: S2034.
  • 24
    Lissiane K, Guedes N, Kowalski SC, Laurindo IM. The new indexes Sdai and Cdai in early arthritis: similar performance to Das 28 index [abstract]. Arthritis Rheum 2006; 54 Suppl 9: S2067.
  • 25
    Smolen J, van der Heijde D, Aletaha D, Pedersen R, Fatenejad S, Chang D, et al. A clinical score that does not require an acute phase response measure, the Clinical Disease Activity Index (CDAI), is of similar value as DAS and DAS28 as an indicator of low disease activity in rheumatoid arthritis [abstract]. Arthritis Rheum 2006; 54 Suppl 9: S199.
  • 26
    Wells GA, Boers M, Shea B, Brooks PM, Simon LS, Strand CV, et al. Minimal disease activity for rheumatoid arthritis: a preliminary definition. J Rheumatol 2005; 32: 201624.
  • 27
    Burmester GR, Mariette X, Montecucco C, Monteagudo-Saez I, Malaise M, Tzioufas AG, et al. Adalimumab alone and in combination with disease-modifying antirheumatic drugs for the treatment of rheumatoid arthritis in clinical practice: the Research in Active Rheumatoid Arthritis (ReAct) trial. Ann Rheum Dis 2007; 66: 7329.
  • 28
    Bombardieri S, Ruiz AA, Fardellone P, Geusens P, McKenna F, Unnebrink K, et al, on behalf of the Research in Active Rheumatoid Arthritis (ReAct) Study Group. Effectiveness of adalimumab for rheumatoid arthritis in patients with a history of TNF-antagonist therapy in clinical practice. Rheumatology (Oxford) 2007; 46: 11919.
  • 29
    Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31: 31524.
  • 30
    Van Gestel AM, Prevoo ML, van 't Hof MA, van Rijswijk MH, van de Putte LB, van Riel PL. Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis: comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism Criteria. Arthritis Rheum 1996; 39: 3440.
  • 31
    Krishnan E, Hakkinen A, Sokka T, Hannonen P. Impact of age and comorbidities on the criteria for remission and response in rheumatoid arthritis. Ann Rheum Dis 2005; 64: 13502.
  • 32
    Hyrich KL, Symmons DP, Watson KD, Silman AJ, on behalf of the British Society for Rheumatology Biologics Register. Comparison of the response to infliximab or etanercept monotherapy with the response to cotherapy with methotrexate or another disease-modifying antirheumatic drug in patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum 2006; 54: 178694.
  • 33
    Hyrich KL, Watson KD, Silman AJ, Symmons DP, and the British Society for Rheumatology Biologics Register. Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. Rheumatology (Oxford) 2006; 45: 155865.
  • 34
    Listing J, Strangfeld A, Rau R, Kekow J, Gromnica-Ihle E, Klopsch T, et al. Clinical and functional remission: even though biologics are superior to conventional DMARDs overall success rates remain low: results from RABBIT, the German biologics register. Arthritis Res Ther 2006; 8: R66.
  • 35
    Verstappen SM, van Albada-Kuipers GA, Bijlsma JW, Blaauw AA, Schenk Y, Haanen HC, et al, and the Utrecht Rheumatoid Arthritis Cohort Study Group (SRU). A good response to early DMARD treatment of patients with rheumatoid arthritis in the first year predicts remission during follow up. Ann Rheum Dis 2005; 64: 3843.
  • 36
    Wells GA, Boers M, Li T, Tugwell P. Validation of minimal disease activity for rheumatoid arthritis patients treated with the biologic therapy abatacept [abstract]. Arthritis Rheum 2006; 54 Suppl 9: S3845.
  • 37
    Weinblatt ME, Keystone EC, Furst DE, Moreland LW, Weisman MH, Birbara CA, et al. Adalimumab, a fully human anti–tumor necrosis factor α monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA Trial [published erratum appears in Arthritis Rheum 2003;48:855]. Arthritis Rheum 2003; 48: 3545.
  • 38
    Keystone EC, Kavanaugh AF, Sharp JT, Tannenbaum H, Hua Y, Teoh LS, et al. Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti–tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial. Arthritis Rheum 2004; 50: 140011.
  • 39
    Montecucco C. Remission, a therapeutic goal in inflammatory arthropathies? Clinical data from adalimumab studies. Drugs 2006; 66: 178395.
  • 40
    Van Vollenhoven RF, Ernestam S, Harju A, Bratt J, Klareskog L. Etanercept versus etanercept plus methotrexate: a registry-based study suggesting that the combination is clinically more efficacious. Arthritis Res Ther 2003; 5: R34751.
  • 41
    Klareskog L, van der Heijde D, de Jager JP, Gough A, Kalden J, Malaise M, et al, and the TEMPO (Trial of Etanercept and Methotrexate with Radiographic Patient Outcomes) Study Investigators. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet 2004; 363: 67581.
  • 42
    Van der Heijde D, Klareskog L, Boers M, Landewe R, Codreanu C, Bolosiu HD, et al, and the TEMPO Investigators. Comparison of different definitions to classify remission and sustained remission: 1 year TEMPO results. Ann Rheum Dis 2005; 64: 15827.
  • 43
    Forslind K, Hafstrom I, Ahlmen M, Svensson B, and the BARFOT Study Group. Sex: a major predictor of remission in early rheumatoid arthritis? Ann Rheum Dis 2007; 66: 4652.
  • 44
    Felson DT, Anderson JJ, Boers M, Bombardier C, Furst D, Goldsmith C, et al. American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995; 38: 72735.